Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Stauch · SciRah

Researcher profile · Semantic Scholar

M. Stauch

Share profile

M. Stauch — researcher profile on SciRah

h-index: 30
Works: 198
Citations: 6,434

Most-cited papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
V. Heinemann, L. V. von Weikersthal, T. Decker, A. Kiani +23 more
2014The Lancet Oncology1,661 citations
Semantic Scholar
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
M. Rummel, N. Niederle, G. Maschmeyer, G. Banat +16 more
2013The Lancet1,435 citations
Semantic Scholar
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
S. Stintzing, D. Modest, Lisa Rossius, M. Lerch +19 more
2016The Lancet Oncology390 citations
Semantic Scholar
Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.
U. Pelzer, B. Opitz, G. Deutschinoff, M. Stauch +11 more
2015Journal of Clinical Oncology257 citations
Semantic Scholar
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
M. Rummel, U. Kaiser, C. Balser, M. Stauch +15 more
2016The Lancet Oncology143 citations
Semantic Scholar
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
J. Sehouli, D. Stengel, G. Oskay-Oezcelik, A. Zeimet +7 more
2008Journal of Clinical Oncology139 citations Open access
Semantic Scholar
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
S. Stintzing, L. Miller-Phillips, D. Modest, L. V. von Weikersthal +16 more
2017European Journal of Cancer136 citations
Semantic Scholar
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
D. Modest, S. Stintzing, L. V. von Weikersthal, T. Decker +15 more
2015Journal of Clinical Oncology129 citations Open access
Semantic Scholar
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
N. Moosmann, L. V. von Weikersthal, U. Vehling-Kaiser, M. Stauch +16 more
2011Journal of Clinical Oncology114 citations
Semantic Scholar
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials
V. Goede, P. Cramer, R. Busch, M. Bergmann +8 more
2014Haematologica111 citations Open access
Semantic Scholar
A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer
H. Riess, A. Helm, M. Niedergethmann, I. Schmidt-Wolf +6 more
2005106 citations
Semantic Scholar
Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).
V. Heinemann, L. V. von Weikersthal, T. Decker, A. Kiani +16 more
201394 citations
Semantic Scholar
The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic leukemia.
P. Langerbeins, Can Zhang, S. Robrecht, P. Cramer +20 more
2021Blood90 citations
Semantic Scholar
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.
M. Rummel, G. Maschmeyer, A. Ganser, A. Heider +15 more
201782 citations
Semantic Scholar
A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial.
H. Riess, U. Pelzer, B. Opitz, M. Stauch +6 more
201078 citations
Semantic Scholar
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).
M. Rummel, U. von Gruenhagen, N. Niederle, F. Rothmann +16 more
200774 citations
Semantic Scholar
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.
M. Rummel, N. Niederle, G. Maschmeyer, A. Banat +14 more
2012Journal of Clinical Oncology73 citations
Semantic Scholar
Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).
V. Heinemann, Ludwig Fischer von Weikersthal, T. Decker, A. Kiani +16 more
2013Journal of Clinical Oncology69 citations
Semantic Scholar
Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.
V. Heinemann, D. Modest, L. V. von Weikersthal, T. Decker +15 more
201456 citations
Semantic Scholar
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Ludwig Fischer von Weikersthal, A. Schalhorn, M. Stauch, D. Quietzsch +16 more
2011European Journal of Cancer50 citations
Semantic Scholar
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)
M. Rummel, U. Kaiser, C. Balser, M. Stauch +12 more
201050 citations
Semantic Scholar
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)
M. Rummel, U. von Gruenhagen, N. Niederle, Harald E. Balló +10 more
200849 citations
Semantic Scholar
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)
P. Cramer, S. Isfort, J. Bahlo, S. Stilgenbauer +15 more
2015Haematologica36 citations Open access
Semantic Scholar
No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).
B. Eichhorst, R. Busch, M. Stauch, M. Bergmann +9 more
200735 citations
Semantic Scholar
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial)
A. Stähler, V. Heinemann, C. Gießen-Jung, A. Crispin +13 more
2016International Journal of Cancer33 citations Open access
Semantic Scholar
Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
S. Stintzing, K. Heinrich, D. Tougeron, D. Modest +16 more
202131 citations
Semantic Scholar
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL
P. Langerbeins, J. Bahlo, C. Rhein, H. Gerwin +21 more
2019Hematological Oncology31 citations
Semantic Scholar
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
M. Michl, S. Stintzing, L. V. von Weikersthal, T. Decker +18 more
2016Annals of Oncology31 citations Open access
Semantic Scholar
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
A. Stahler, S. Stintzing, D. Modest, I. Ricard +16 more
2020Clinical Cancer Research27 citations
Semantic Scholar
O-0030INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306)
V. Heinemann, D. Modest, L. V. von Weikersthal, T. Decker +15 more
201425 citations Open access
Semantic Scholar
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer
A. Stahler, V. Heinemann, J. Neumann, A. Crispin +15 more
2017Anti-Cancer Drugs23 citations
Semantic Scholar
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
T. Elter, R. James, Raymonde Busch, D. Winkler +16 more
2012Leukemia22 citations Open access
Semantic Scholar
Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study
K. Ridwelski, J. Fahlke, E. Kettner, C. Schmidt +6 more
200522 citations
Semantic Scholar
Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study
M. John, A. Hinke, M. Stauch, H. Wolf +4 more
2012BMC Cancer21 citations Open access
Semantic Scholar
Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)
D. Modest, S. Stintzing, Ludwig Fischer von Weikersthal, T. Decker +16 more
2017International Journal of Cancer20 citations Open access
Semantic Scholar
Plasma levels after a single oral dose of proscillaridin
G. Belz, M. Stauch, G. Rudofsky
2004European Journal of Clinical Pharmacology20 citations
Semantic Scholar
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry
S. Al-Batran, R. Hofheinz, Alexander Reichart, C. Pauligk +52 more
2020International Journal of Cancer17 citations Open access
Semantic Scholar
Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group
V. Heinemann, L. V. von Weikersthal, U. Vehling-Kaiser, M. Stauch +6 more
200817 citations
Semantic Scholar
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
L. Fischer, S. Stintzing, L. V. von Weikersthal, D. Modest +22 more
2022British Journal of Cancer16 citations Open access
Semantic Scholar
Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).
N. Moosmann, L. V. von Weikersthal, U. Vehling-Kaiser, M. Stauch +5 more
201016 citations
Semantic Scholar
Costs of treatment of colorectal cancer in different settings in Germany
K. Hieke, U. Kleeberg, M. Stauch, A. Grothey
2004The European Journal of Health Economics, formerly: HEPAC16 citations
Semantic Scholar
Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients
M. Rummel, K. Heine, H. Bodenstein, M. Baldus +4 more
200815 citations
Semantic Scholar
A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial.
H. Riess, U. Pelzer, G. Deutschinoff, B. Opitz +6 more
2009Journal of Clinical Oncology14 citations
Semantic Scholar
The effect of various cardenolides and bufadienolides with different cardiac activity on the 86Rubidium uptake of human erythrocytes
G. Belz, M. Stauch, H. Kurbjuweit, A. Oberdorf
2004Naunyn-Schmiedeberg's Archives of Pharmacology13 citations
Semantic Scholar
Fludarabine induces higher response rates in first line therapy of older patients with advanced chronic lymphocytic leukemia than chlorambucil Interim analysis of a phase III study of the German CLL Study Group
B. Eichhorst, R. Busch, M. Stauch, M. Kneba +9 more
200313 citations
Semantic Scholar
O-0029FOLFIRI PLUS CETUXIMAB VERSUS FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF KRAS-WILDTYPE METASTATIC COLORECTAL CANCER: GERMAN AIO STUDY KRK-0306 (FIRE-3)
D. Modest, L. V. von Weikersthal, S. Stintzing, T. Decker +16 more
201312 citations Open access
Semantic Scholar
Comparison of whole-Body Thallium Imaging with Transcutaneous PO2 in Studying Regional Blood Supply in Patients with Peripheral Arterial Occlusive Disease
Yue-Fei Liu, J. Steinacker, A. Opitz-Gress, M. Clausen +1 more
1996Angiology12 citations
Semantic Scholar
Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial.
S. Stintzing, A. Jung, Christine Kapaun, Jana A. Reiche +8 more
201211 citations
Semantic Scholar
Impaired granulocytic function in patients with acute leukaemia: only partial normalisation after successful remission-inducing treatment
W. Hofmann, M. Stauch, K. Höffken
2012Journal of Cancer Research and Clinical Oncology11 citations Open access
Semantic Scholar
Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group
P. Jenke, B. Eichhorst, R. Busch, Nadine Anheier +13 more
201111 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

V. Heinemann×19
Invite
V. Heinemann — researcher profile on SciRah
U. Vehling-Kaiser×19
Invite
U. Vehling-Kaiser — researcher profile on SciRah
S. Stintzing×18
Invite
S. Stintzing — researcher profile on SciRah
D. Modest×17
Invite
D. Modest — researcher profile on SciRah

L. V. von Weikersthal

×15

Invite

L. V. von Weikersthal — researcher profile on SciRah

Invite

A. Jung — researcher profile on SciRah

Invite

T. Decker — researcher profile on SciRah

Invite

A. Kiani — researcher profile on SciRah

Invite

C. Kahl — researcher profile on SciRah

S. Al-Batran×12

Invite

S. Al-Batran — researcher profile on SciRah

T. Kirchner×12

Invite

T. Kirchner — researcher profile on SciRah

T. Heintges×11

Invite

T. Heintges — researcher profile on SciRah